FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
4D Molecular Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$12.29+0.15 (+1.24%)
Close on Oct 19, 2026
- Market cap
- $863.64M
- P/E (TTM)
- –
- Dividend yield
- –
4D Molecular Therapeutics, Inc. revenue by segment
By business segment
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Japan | $85.00M | $0 | – | – | – | – | – | 99.8% | – |
| United States | $209.00K | $37.00K | $20.16M | $35.00K | $121.00K | -$27.00K | $666.00K | 0.2% | +464.9% |
| Netherlands | – | $0 | $567.00K | $3.09M | $736.00K | $742.00K | $26.00K | – | – |
| Australia | – | – | – | – | – | $0 | $7.00K | – | – |
| Switzerland | – | – | – | $0 | $17.18M | $12.90M | $6.29M | – | – |
From the segment and revenue-disaggregation notes of 4D Molecular Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.